EF Hutton Reiterates Buy on Pasithea Therapeutics, Maintains $2 Price Target
EF Hutton Assumes Pasithea Therapeutics at Buy, Announces Price Target of $2
EF Hutton Adjusts Price Target on Pasithea Therapeutics to $2 From $2.30, Maintains Buy Rating
EF Hutton Maintains Buy on Pasithea Therapeutics, Lowers Price Target to $2
No Data
No Data